SNY CHMP opinion: Thursday, July 23, 2026
Variation type II · Suliqua · Update of sections 4.2, 4.8, and 5.1 of the SmPC in order to introduce a new posology regimen based on final results from study LPS17008 (SoliSwitch); this is a 24-week, single-arm, phase 4 clinical study to evaluate the efficacy and safety of switching to iGlarLixi in
Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.
Every date on this page is free — forever.
A free account adds the interactive calendar with US/EU filters and watchlists. Investor (€19/mo) adds Impact Forecasts on each event, date-slip tracking and calendar sync (Google/Apple/Outlook). Pro adds the full analytics stack.